GLP-1 receptor agonists are safe to use in patients with DKD who have stage 5 CKD, despite the fact that they can be given to patients with CKD and an eGFR as low as 15 mL/min/1.73 m2 [29]. This evidence concerns the gene GLP1R and diabetic kidney disease.